drugset / Trial / NCT05063734
A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is conducted to select the THR-687 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).
Timeline
- Start
- 2021-08-27
- Primary completion
- 2022-06-29
- Completion
- 2022-06-29
Outcome
Outcome not reported
Stopped: “Based on data obtained in Part A, there was insufficient evidence of efficacy on the key outcome measures. As a result, the study was not advanced to Part B.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | THR-687 | Unknown | 1.2 mg | Intravitreal |
| Subject | THR-687 | Unknown | 2 mg | Intravitreal |